Following the recent release of Boston Scientific’s Q2 financial information;

Dominic Tong, Senior Medical Device Analyst at GlobalData, a leading data and analytics company, offers his view:

“Boston Scientific reported a Q2 2021 growth of 101.5% in its neuromodulation segment to a revenue of $247m compared to Q2 2020’s revenue of $122m, though this figure must be kept in the context of the COVID-19 pandemic. Q2 2020 saw widespread delays of elective procedures across the globe, including neuromodulation procedures, in the face of the first wave of COVID-19.

“However, the Q2 2021 neuromodulation revenue still represents a 21% increase compared to Boston Scientific’s Q2 2019 neuromodulation revenue. Additionally, its Q2 neuromodulation revenue was a 24% increase compared to Q1 2021. This growth was expected, though still reassuring, as the delayed procedures from 2020 are being completed now with vaccine rates increasing and COVID-19 cases declining.

“Boston Scientific will still need strong Q3 and Q4 performances in the neuromodulation segment to recoup its losses in 2020. New, more transmissible COVID-19 variants such as Delta, along with lagging vaccination rates in some countries, may hinder that recovery if hospital systems are again overwhelmed by an outbreak of cases.”